Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients

Renal Failure

Volumn 32, Issue 9, 2010, Pages 1031-1035

  Hassan, Kamal S ^a   Hassan, Shadi K ^b   Hijazi, Ehsan G ^a   Khazim, Khalid O ^a  

^a WESTERN GALILEE HOSPITAL   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

Author keywords

inflammation markers; lipid profile; omega 3; peritoneal dialysis; triglycerides

Indexed keywords

4 HYDROXYNONENAL; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATINE KINASE; DOCOSAHEXAENOIC ACID; FIBRINOGEN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICODEXTRIN; ICOSAPENTAENOIC ACID; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; KIDNEY FAILURE; MALE; PERITONEAL DIALYSIS; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; LIPIDS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PILOT PROJECTS;

EID: 77957252480     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.510231     Document Type: Article

References (29)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003;108:2154-2169. (Pubitemid 37337595)
2. Locatelli F, Covic A, Chazot C, Leunissen K, Luño J, Yaqoob M. Accorde Programme. Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant. 2004;19(5):1058-1068. (Pubitemid 38628122)
3. Eknoyan G. Cardiovascular mortality and morbidity in dialysis patients. Mineral Electrolyte Metab. 1999;25:100-104. (Pubitemid 29196643)
4. Locatelli F, Marcelli D, Conte F, et al. Cardiovascular disease in chronic renal failure: The challenge continues. Nephrol Dial Transplant. 2000;15(Suppl. 5):69-80.
5. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(Suppl. 3):S112-S119. (Pubitemid 28527268)
6. Zimmerman J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648-658. (Pubitemid 29082891)
7. Vaziri ND, Gonzales EC, Wang J, Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: Effect of hemodialysis. Am J Kidney Dis. 1994;23: 828-834. (Pubitemid 24173566)
8. Coresh J, Longenecker JC, Miller ER 3rd, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol. 1998;9(Suppl. 12):S24-S30.
9. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;131:607-617. (Pubitemid 28158000)
10. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis. 2000;35:1226-1237.
11. Stenvinkel P, Amann K, Ketteler M. Cardiovascular disease in chronic kidney disease. In: Feehally J, Floege J, Johnson RJ, eds. Comprehensive Clinical Nephrology. 3rd ed., Philadelphia: Mosby Elsevier; 2007:839-852.
12. Liu J, Rosner MH. Lipid abnormalities associated with endstage renal disease. Semin Dial. 2006;19:32-40. (Pubitemid 43479009)
13. Sarah SP. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol. 2003;14:S315-S320. (Pubitemid 37052397)
14. Charles R, Terry A. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51:2375-2384. (Pubitemid 351815163)
15. Friedman A, Moe S. Review of the effects of omega-3 supplementation in dialysis patients. Clin J Am Soc Nephrol. 2006;1: 182-192.
16. Kris-Etherton PM, Taylor DS, Yu-Poth S, et al. Polyunsaturated fatty acids in the food chain in the united states. Am J Clin Nutr. 2000;71:179S-188.S. (Pubitemid 30046114)
17. Gruppo Italiano per lo Studio della Sopravvivenzanell' Infarto Miocardio. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-prevenzione trial. Lancet. 1999;354:447-455.
18. Harris WS. N-3 fatty acids and serum lipoproteins: Human studies. Am J Clin Nutr. 1997;65:S1645-S1654.
19. Dobell E, Chan M, Williams P, Allman M. Food preferences and food habits of patients with chronic renal failure undergoing dialysis. J Am Diet Assoc. 1993;93:1129-1135. (Pubitemid 23320575)
20. Das UN. Essential fatty acids as possible mediators of the actions of statins. Prostaglandins Leukot Essent Fatty Acids. 2001;65(1):37-40.
21. Nakamura N, Hamazaki T, Jokaji H, Minami S, Kobayashi M. Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia. Int J Clin Lab Res. 1998;28(3):192-195. (Pubitemid 28463798)
22. Grimsgaard S, Bonaa KH, Hansen JB, Nordøy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr. 1997; 66(3):649-659. (Pubitemid 27366792)
23. Kelley DS, Siegel D, Fedor DM, Adkins Y, Mackey BE. DHA supplementation decreases serum C-reactive protein and other markers of inflammatory in hypertriglyceridemic men. J Nutr. 2009;139:495-501.
24. Stirban A, Nandrean S, Götting C, et al. Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus. Am J Clin Nutr. 2010;91:808-813.
25. Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: Physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6(3):391-409.
26. Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006; 98(4A): 27i-33i.
27. Khan S, Minihane AM, Talmud PJ, et al. Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. J Lipid Res. 2002;43(6):979-985. (Pubitemid 34602621)
28. Davidson MH, Maki KC, Bays HE, Bays H, Carter R, Ballantyne CM. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol. 2009;3(5):442-1340
29. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17(4):387-393. (Pubitemid 44079475)